NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, today unveiled INB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback